Celecoxib-loaded PLGA/cyclodextrin microspheres: Characterization and evaluation of anti-inflammatory activity on human chondrocyte cultures

Colloids and Surfaces B: Biointerfaces

Volumn 111, Issue , 2013, Pages 289-296

  Cannavà, Carmela ^a   Tommasini, Silvana ^a   Stancanelli, Rosanna ^a   Cardile, Venera ^b   Cilurzo, Felisa ^c   Giannone, Ignazio ^b   Puglisi, Giovanni ^b   Ventura, Cinzia Anna ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Celecoxib; Chondrocyte cultures; Dimethyl cyclodextrin; PLGA microspheres; Release kinetics

Indexed keywords

ANTI-INFLAMMATORY ACTIVITY; CELECOXIB; CHONDROCYTES; ENCAPSULATION EFFICIENCY; PHARMACOLOGICAL ACTIVITY; PLGA MICROSPHERES; RELEASE KINETICS; TECHNOLOGICAL PROPERTIES;

BODY FLUIDS; COPOLYMERS; CYCLODEXTRINS; DRUG PRODUCTS; ENCAPSULATION;

MICROSPHERES;

2,6 O DIMETHYL BETA CYCLODEXTRIN; CELECOXIB; CYCLODEXTRIN; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; MICROSPHERE; NITRIC OXIDE SYNTHASE; POLYGLACTIN; ANTIINFLAMMATORY AGENT; DICLOFENAC; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARTILAGE CELL; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG RELEASE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; EMULSION; ENCAPSULATION; EVAPORATION; EX VIVO STUDY; HUMAN; HUMAN CELL; INFLAMMATION; LOADING DRUG DOSE; PARTICLE SIZE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SUSTAINED RELEASE FORMULATION; CELL CULTURE; CHEMISTRY; CIRCULAR DICHROISM; CYTOLOGY; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DRUG EFFECTS;

ANTI-INFLAMMATORY AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CELECOXIB; CELLS, CULTURED; CHONDROCYTES; CIRCULAR DICHROISM; CYCLODEXTRINS; DICLOFENAC; DIFFUSION; HUMANS; LACTIC ACID; MICROSPHERES; POLYGLYCOLIC ACID; PYRAZOLES; SULFONAMIDES;

EID: 84880368390     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2013.06.015     Document Type: Article

References (38)

1. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N.M., Stenson W.F., Burr A.M., Zhao W.W., Kent J.D., Lefkowith J.B., Werburg K.M., Geiss G.S. JAMA 2000, 284:1247.
2. Bertagnolli M.M., Eagle C.J., Zauber A.G., et al. N. Engl. J. Med. 2006, 355:873.
3. Bing R.J. Curr. Atheroscler. Rep. 2003, 5:114.
4. Marnett L.J. Annu. Rev. Pharmacol. Toxicol. 2009, 49:265.
5. Petit-Zeman S. Nat. Rev. Drug Discov. 2004, 3:726.
6. Topol E.J. N. Engl. J. Med. 2004, 351:1707.
7. Schweitzer A., Hasler-Nguyen N., Zijlstra J. BMC Pharmacol. 2009, 9:5. 10.1186/1471-2210-9-5.
8. Zhang Z., Bi X., Li H., Huang G. Drug Deliv. 2011, 18:536.
9. Ratcliffe J.H., Hunneyball I.M., Wilson C.G., Smith A., Davis S.S. J. Pharm. Pharmacol. 1987, 39:290.
10. Thakkar H., Sharma R.K., Mishra A.K., Chuttani K., Murthy R.R. AAPS PharmSciTech 2005, 6:E65.
11. Thakkar H., Sharma R.K., Mishra A.K., Chuttani K., Murthy R.S. J. Pharm. Pharmacol. 2004, 56:1091.
12. Thakkar H., Sharma R.K., Mishra A.K., Chuttani K., Murthy R.S. J. Drug Target. 2004, 12:549.
13. Fernández-Carballido A., Herrero-Vanrell R., Molina-Martinez I.T., Pastoriza P. Int. J. Pharm. 2004, 279:33.
14. Tunçay M., Calis S., Kas H.S., Ercan M.T., Peksoy I., Hincal A.A. Int. J. Pharm. 2000, 17:179.
15. Annoni G., Strumia E. Celebrex. Il capostipite degli inibitori specifici della COX-2 2000, Springer-Verlag Italia, Milano.
16. Simon L.E., Lanza F.L., Lipsky P.E., Hubbard R.C., Talwalker S., Schwartz B.D., Isakson P.C., Geis G.S. Arthritis Rheum. 1998, 41:1591.
17. Goeschke B., Braathen L.R. Dermatology 2004, 209:53.
18. Marquès S., Milpied B., Foulc P., Barbarot S., Cassagnau E., Stalder J.F. Ann. Dermatol. Venereol. 2003, 130:1051.
19. Yang C.C., Lee J.Y., Chen W.C. J. Formos. Med. Assoc. 2004, 103:555.
20. P. Couvreur, M. Roland, P. Speiser, US Patent 4 (1982), p. 329.
21. Silveira A.M., Ponchel G., Puisieux F., Duchêne D. Pharm. Res. 1998, 15:1051.
22. Cannavà C., Crupi V., Guardo M., Majolino D., Stancanelli R., Tommasini S., Ventura C.A., Venuti V. J. Incl. Phenom. Macrocycl. Chem. 2013, 75:255-262.
23. Ventura C.A., Giannone I., Musumeci T., Pignatello R., Ragni L., Landolfi C., Milanese C., Paolino D., Puglisi G. Eur. J. Med. Chem. 2006, 41:233.
24. Boudad H., Legrand P., Lebas G., Cheron M., Duchêne D., Ponchel G. Int. J. Pharm. 2001, 218:113.
25. Costa P., Lobo J.M.S. Eur. J. Pharm. Sci. 2001, 13:123.
26. Ventura C.A., Giannone I., Paolino D., Pistarà V., Corsaro A., Puglisi G. Eur. J. Med. Chem. 2005, 40:624.
27. Ventura C.A., Tommasini S., Falcone A., Giannone I., Paolino D., Sdrafkakis V., Mondello M.R., Puglisi G. Int. J. Pharm. 2006, 314:37.
28. Zhang H., Gao S. Int. J. Pharm. 2007, 329:122.
29. Okada H., Doken Y., Ogawa Y., Toguchi H. Pharm. Res. 1994, 11:1143.
30. Freiberg S., Zhu X. Int. J. Pharm. 2004, 282:1.
31. Huang X., Brazel C.S. J. Controlled Release 2001, 73:121.
32. Makadia H.K., Siegel S.J. Polymers 2001, 3:1377.
33. Harata K., Uedaira H. Bull. Chem. Soc. Jpn. 1975, 48:375.
34. Allenmark S. Chirality 2003, 15:409.
35. Yang S.F., Hsieh Y.S., Lue K.H., Chu S.C., Chang I.C., Lu K.H. Clin. Biochem. 2008, 41:109.
36. Gika H.G., Theodoridou A., Michopoulos F., Theodoridis G., Diza E., Settas L., Nikolaidis P., Smith C., Wilson I.D. J. Pharm. Biomed. Anal. 2009, 49:579.
37. Puglisi G., Fresta M., Ventura C.A. J. Colloid Interface Sci. 1996, 80:542.
38. Ventura C.A., Fresta M., Paolino D., Pedotti S., Corsaro A., Puglisi G. J. Drug Target. 2001, 9:379.